EMEA-002708-PIP02-21 - paediatric investigation plan

verdiperstat

Key facts

• Active substance:
  verdiperstat
• Therapeutic area:
  Neurology
• Decision number:
  P/0523/2021
• PIP number:
  EMEA-002708-PIP02-21
• Pharmaceutical form(s):
  Modified-release tablet
• Condition(s) / indication(s):
  Treatment of amyotrophic lateral sclerosis
• Route(s) of administration:
  Oral use
• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  03/12/2021
• Compliance check done:
  No

Decision

P/0523/2021 : EMA Decision of 3 December 2021 on the granting of a product specific waiver for verdiperstat (EMEA-002708-PIP02-21)

Adopted Reference Number: EMA/623923/2021